01-01-1970 12:00 AM | Source: Reuters
India's Sun Pharma to acquire U.S.-based Concert for $576 million
Sun Pharmaceutical Industries Limited said on Thursday it will acquire U.S.-based Concert Pharmaceuticals for $576 million in cash to gain access to an experimental drug for treating patchy baldness.
Concert's lead candidate, deuruxolitinib, is being evaluated as a treatment for autoimmune condition alopecia areata, which results in patchy hair loss.
India's Sun Pharma said it will commence a tender offer to acquire Concert at $8 per share, a premium of 16% to the stock's last close.
Concert stockholders will also receive a contingent value right entitling them an additional amount of up to $3.50 per share of common stock in cash, contingent on sales milestones.
Latest News
Evening Roundup : A Daily Report on Bullion Energy &...
Market Wrap Up by Shrikant Chouhan, Head Equity Rese...
Gold Special Report: Akshaya Tritiya 2024 by Religar...
FIIs stood as net sellers in equities as per May 09 ...
Perspective On AMFI Data by Sanjay Agarwal, Senior D...
Post market comment by Mandar Bhojane, Research Anal...
Daily Market Analysis : The market resumed its corre...
Indian shares drop most in three months; L&T drags
VC firm Venturi Partners invests $27 mn in K12 Techn...
TCS CEO Krithivasan earned $3 million in first year ...